A Novel Method for the Quantification of Adeno-Associated Virus Vectors for RNA Interference Applications Using Quantitative Polymerase Chain Reaction and Purified Genomic Adeno-Associated Virus DNA as a Standard

Abstract

Recombinant adeno-associated virus (rAAV) vectors are promising tools in gene therapy, but accurate quantification of the vector dose remains a critical issue for their successful application. We therefore aimed at the precise determination of the titer of self-complementary AAV (scAAV) vectors to improve the reliability of RNA interference (RNAi)-mediated knockdown approaches. Vector titers were initially determined by quantitative polymerase chain reaction (qPCR) using four primer sets targeting different regions within the AAV vector genome (VG) and either coiled or linearized plasmid standards. Despite very low variability between replicates in each assay, these quantification experiments revealed up to 20-fold variation in vector titers. Therefore, we developed a novel approach for the reproducible determination of titers of scAAV vectors based on the use of purified genomic vector DNA as a standard (scAAV_Std). Consistent results were obtained in qPCR assays using the four primer sets mentioned above. RNAi-mediated silencing of human cyclophilin B (hCycB) by short hairpin RNA-expressing scAAV vectors was investigated in HeLa cells using two independent vector preparations. We found that the required vector titers for efficient knockdown differed by a factor of 3.5 between both preparations. Hence, we also investigated the number of internalized scAAV vectors, termed transduction units (TUs). TUs were determined by qPCR applying the scAAV_Std. Very similar values for 80% hCycB knockdown were obtained for the two AAV vector preparations. Thus, only the determination of TUs, rather than vector concentration, allows for reproducible results in functional analyses using AAV vectors.

Get full access to this article

View all access options for this article.

References

Atchison

R.W.

, et al. (1965). Adenovirus-associated defective virus particles. Science, 149, 754–756.

Aucoin

M.G.

, et al. (2008). Critical assessment of current adeno-associated viral vector production and quantification methods. Biotechnol. Adv., 26, 73–88.

Aurnhammer

, et al. (2012). Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods, 23, 18–28.

Berk

A.J.

(2007). Adenoviridae: the viruses and their replication. In Fields Virology. Knipe

D.M.

and Howley

P.M.

, eds. (Lippinocott Williams & Wilkins, Philadelphia, PA), pp. 2355–2394.

Carpentier

A.C.

, et al. (2012). Effect of alipogene tiparvovec (AAV1-LPL(S447×)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab., 97, 1635–1644.

Daya

, and Berns

K.I.

(2008). Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev., 21, 583–593.

Fagone

, et al. (2012). Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods. Hum. Gene Ther. Methods, 23, 1–7.

Fechner

, et al. (2008). Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J. Mol. Med., 86, 987–997.

Gao

G.P.

, et al. (2000). Production of recombinant adeno-associated virus. Adv. Virus Res., 55, 529–543.

10.

Gaudet

, et al. (2012). Gene therapy for lipoprotein lipase deficiency. Curr. Opin. Lipidol., 23, 310–320.

11.

Gaudet

, et al. (2013). Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL(S447×)) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther., 20, 361–369.

12.

Grieger

J.C.

, et al. (2006). Production and characterization of adeno-associated viral vectors. Nat. Protoc., 1, 1412–1428.

13.

Grieger

J.C.

, and Samulski

R.J.

(2012). Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol., 507, 229–254.

14.

Grimm

, and Kay

M.A.

(2007). RNAi and gene therapy: a mutual attraction. Hematology Am. Soc. Hematol. Educ. Program., 2007, 473–481.

15.

Grimm

, et al. (1999). Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther., 6, 1322–1330.

16.

Grimm

, et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 441, 537–541.

17.

Henke

, et al. (1997). Betaine improves the PCR amplification of GC-rich DNA sequences. Nucleic Acids Res., 25, 3957–3958.

18.

Kapranov

, et al. (2012). Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum. Gene Ther., 23, 46–55.

19.

Kienle

, et al. (2012). Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling. J. Vis. Exp., 62, e3819.

20.

Kim

S.J.

, et al. (2009). Effective relief of neuropathic pain by adeno-associated virus-mediated expression of a small hairpin RNA against GTP cyclohydrolase 1. Mol. Pain, 5, 67.

21.

Kwon

, and Schaffer

D.V.

(2008). Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm. Res., 25, 489–499.

22.

Ling

, et al. (2011). High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors. J. Vis. Exp., 49, 2538.

23.

Lock

, et al. (2010). Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum. Gene Ther., 21, 1273–1285.

24.

Mayginnes

J.P.

, et al. (2006). Quantitation of encapsidated recombinant adeno-associated virus DNA in crude cell lysates and tissue culture medium by quantitative, real-time PCR. J. Virol. Methods, 137, 193–204.

25.

McCarty

D.M.

, et al. (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther., 8, 1248–1254.

26.

McCarty

D.M.

, et al. (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther., 10, 2112–2118.

27.

McClure

, et al. (2011). Production and titering of recombinant adeno-associated viral vectors. J. Vis. Exp., 57, e3348.

28.

Rohr

U.P.

, et al. (2002). Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J. Virol. Methods, 106, 81–88.

29.

Rohr

U.P.

, et al. (2005). Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles. J. Virol. Methods, 127, 40–45.

30.

Rothe

, et al. (2010). Rapid construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30. Oligonucleotides, 20, 191–198.

31.

Sommer

J.M.

, et al. (2003). Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol. Ther., 7, 122–128.

32.

Storek

, et al. (2006). Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Mol. Pain, 2, 4.

33.

Storek

, et al. (2008). Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc. Natl. Acad. Sci. USA, 105, 1055–1060.

34.

Thomas

C.E.

, et al. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol., 78, 3110–3122.

35.

Van Vliet

K.M.

, et al. (2008). The role of the adeno-associated virus capsid in gene transfer. Methods Mol. Biol., 437, 51–91.

36.

Veldwijk

M.R.

, et al. (2002). Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther., 6, 272–278.

37.

, et al. (2006). Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther., 14, 316–327.

38.

, et al. (2003). Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors. Hum. Gene Ther., 14, 897–906.

39.

Yang

, et al. (2011). Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol. Biol., 709, 127–139.

40.

Zen

, et al. (2004). Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events. Hum. Gene Ther., 15, 709–715.

41.

Zolotukhin

, et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther., 6, 973–985.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.14 MB

0.03 MB

0.02 MB